drugset / Trial / NCT05834543
Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined chemotherapy. The primary efficacy outcomes are progression free survival (PFS) and objective response rate (ORR).
Timeline
- Start
- 2023-05-26
- Primary completion
- 2024-10-23
- Completion
- 2025-03-03
Outcome
Outcome not reported
Stopped (Business): “This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2618 | Monoclonal antibody | — | — |
| Subject | TQB3617 | Unknown | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Penpulimab | Monoclonal antibody | — | — |